Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan phase 3 trial in true resistant hypertension
NL-OMON48671Phase 3Completed
- Sponsor
- Idorsia
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprocitentan in resistant hypertension (RH) (3 arms), sponsored by Idorsia. Primary endpoint: Change from baseline to Week 4 in mean trough sitting systolic blood pressure. Started Nov 2018; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NL-OMON48671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48671.